Business
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"\n Royalty revenue contribution expected to begin as early as 2030\n \n \n Initial partner targets include derisked MoAs that are approved blockbusters today\n \n \n Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation\n \n \n Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier \n \n \n Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET\n \n \n SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. (\"Elektrofi\"), a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon™. The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi.\n The Hypercon™ technology is an innovative microparticle approach that sets a new standard in the pursuit of hyper concentration, enabling high protein concentrations while maintaining syringeability, which is the ability to inject smoothly and easily. Hypercon™ enables biologic product formulation concentrations of 400-500 mg/ml, which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today. The increased concentration reduces the volume of injection for the same dosage and will create more opportunities for at-home and HCP office delivery, including via small volume auto-injector or with Halozyme's innovative high volume auto-injector.\n \"This acquisition marks a pivotal step in Halozyme's evolution. With Elektrofi's Hypercon technology, we are expanding and diversifying our drug delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi's licensing, royalty revenue business model,\" said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. \"We look forward to welcoming Elektrofi's talented team as we embark on our next chapter of drug delivery innovation to continue to drive va...